MDM2 at BIO 2025: Arizona’s MedTech Momentum Meets the Global Stage

In June 2025, Greater Phoenix’s Medical Device Manufacturing Multiplier Consortium, MDM2, had the privilege of attending the 2025 BIO International Convention at the Boston Convention & Exhibition Center. As MDM2 is a regional consortium supporting the next generation of medical devices augmented with artificial intelligence (AI) and automated systems, we attended the BIO 2025 to help showcase Greater Phoenix’s momentum as a national leader in next-generation MedTech. 

The convention’s theme this year, “The World Can’t Wait”, emphasized the importance of accelerating the delivery of new biotechnology discoveries into solutions for patients. BIO 2025’s topics included artificial intelligence, automation of manufacturing processes and improved patient monitoring aligned well with MDM2’s regional strategy.

Arizona MedTech innovators connected throughout the week with global leaders who are transforming the healthcare space with technology. 

Automation Takes Center Stage

At BIO 2025, MDM2 representatives met with groundbreaking companies that are building devices that automate some of the world’s most important bio-processes, surgical robotics and devices. With City of Phoenix as a main sponsor, our MDM2 Regional Innovation Officer, Chris Yoo helped judge several promising new companies, including startups from Arizona at BIO 2025’s Start-Up Stadium, a presentation event that gave 50+ start-up finalists the opportunity to win prizes. 

Several examples of the convergence of semiconductor technologies and medical devices were on display, including for example PinPrint, an innovator applying semiconductor printing techniques to vaccination and drug treatment needs.

Learning From Artificial Intelligence in Healthcare

AI is redefining how we think about diagnostics, care delivery and patient delivery. It’s no surprise it was another common topic in many segments of the conference and a reflection of where the biopharmaceutical and medical device fields are heading. 

As AI technology is driven by semiconductors, Arizona is uniquely positioned to make advancements in the AI healthcare space due to the state’s strong presence in both semiconductor and medical device industries. AI development in healthcare means improved patient care.

These themes mirror many of the foundational strategies laid out in MDM2’s implementation plan. MDM2 recognizes that AI is not an isolated vertical, but rather a force that touches every part of the healthcare and life sciences value chain. 

BIO 2025 reinforced the idea that we’re on the right path. Arizona is doubling down on technology in healthcare and is leading the charge in closed-loop medical device systems.  

Intelligent Devices & the Digital Shift

Another dominant theme at BIO 2025 was the ever-improving personalization of therapy based on more intelligent systems, capture of longitudinal data and incorporation of better information into therapeutic development. AI and other key enabling technologies, like wearable diagnostics and closed-loop therapeutics, are enabling care to become more connected, adaptive, and personalized.

In Arizona, MDM2’s growth strategy supports this evolution, by focusing on integrated innovation hubs. These hubs foster the design and production of intelligent devices, by leveraging regional assets, including pilot facilities, workforce pipelines and university partnerships. 

Infrastructure & Ecosystems for Innovation

BIO 2025 made clear that global innovation is only scalable when matched with the right infrastructure, and that biomanufacturing in synergy with medical device manufacturing will result in faster-to-develop, more relevant solutions for patients. 

Arizona’s vision for medical device manufacturing includes a sector-based approach that supports full lifecycle development. The region’s investment in connected infrastructure and accessible funding pathways is what allows new ideas to scale. 

MDM2’s presence at BIO 2025 with key stakeholders in the ecosystem, such as the City of Phoenix, Flinn Foundation, Phoenix Bioscience Core, Mayo Clinic Discovery Oasis and others, aligned perfectly with conversations about building strong regional ecosystems that are built for scale.

BIO reinforced the value of the MDM2 consortium model and proved that when partners align around shared goals, regional ecosystems become national growth engines.

Looking Ahead

Attending BIO 2025 was just the beginning for MDM2 and its consortium members. As we look forward to the rest of the year and beyond, MDM2 plans to pursue next steps that include:

• Continued discussions with medical device start-ups and investors

• Scaling talent pipelines and commercialization infrastructure

• Amplifying the Phoenix MedTech mission and story to national audiences

  
  

Arizona’s MedTech Message Is Clear: We’re Focused on Innovation

Arizona is stepping forward with a clear vision for the future of medical technology. Through MDM2, the state is creating the environment where innovation thrives, by bringing together talent, infrastructure and intelligent systems to accelerate real-world impact.